| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 黄光伟 | 0 | 5.33% | — | 6 months |
| 苏州策源扶海企业管理合伙企业(有限合伙) | 0 | 38.94% | — | 6 months |
| 天士力(国际)医疗健康投资发展有限公司 | 0 | 13.33% | — | 6 months |
| 天士力(香港)医药投资有限公司 | 0 | 6.67% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO saw a modest oversubscription of 11.39 times, paired with a high hit rate of 68.57%, reflecting tepid investor enthusiasm. The reallocation from the international tranche to the Hong Kong public offering further underscores weaker-than-expected demand. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
The top of the A-tier (甲尾) and the bottom of the B-tier (乙头) both anticipated a single lot, despite application amounts of HK$1,000,000 and HK$2,000,000 respectively. This indicates that the B-head allocation was disproportionately costly, reducing efficiency for larger subscribers. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Mainland Chinese investors dominated the applicant pool at 87.6%, signaling strong cross-border demand for this biotech listing. The demographic profile skews male (62.3%) with an average age of 43, typical of experienced investors in this segment. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Brainaurora-B (06681): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

